LUXLung8_3A | R Documentation |
Kaplan-Meier digitized data from LUXLung8, figure 3A (PMID 26156651). A reported sample size of 795 for a primary endpoint of PFS in lung cancer.
LUXLung8_3A
A data frame of 795 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (afatinib, erlotinib) | |
Soria J-C, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015; 16: 897–907.
summary(LUXLung8_3A)
kmplot(LUXLung8_3A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.